Our results provide the basis for an integrated pathological and molecular genetic classification of ccRCC, which takes into account disease-specific panels of genes, such as VHL, BAP1, PBRM1 and SETD2, thereby paving the way for subtype-specific treatments that exploit genetic abnormalities. The gene discussed is BAP1; the disease is nonpapillary renal cell carcinoma.